All In Biotech

NDA 205909 · Praxair Distribution INC

Medical Air, Usp

Medical Air · Inhalation

Last checked: Nov 20, 2026Latest source record: Aug 5, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Aug 5, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

698

91 Phase 3, 71 recruiting

FAERS reports

18

16 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 21, 2024.

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 5, 2013 Original approval · Medical Gas Letter
1 products under this application
  • MEDICAL AIR, USP · MEDICAL AIR N/A · GAS, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Medical Air" as an intervention, any sponsor and status, largest first.

All 698 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction3
  • atrial fibrillation2
  • blood pressure decreased2
  • cardiac arrest2
  • cyanosis2
  • dystonia2
  • oxygen saturation decreased2
  • polyuria2
  • sinus tachycardia2
  • acidosis1
  • alanine aminotransferase increased1
  • anaesthetic complication cardiac1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20051
20062
20071
20081
20091
20111
20121
20141
20171
20213
20232
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 64 on PubMed

Sponsor: Praxair Distribution INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.